Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis - PubMed (original) (raw)
. 2012 Nov;44(11):1179-81.
doi: 10.1038/ng.2413. Epub 2012 Sep 23.
Jay P Patel, Maria E Figueroa, Aparna Vasanthakumar, Sylvie Provost, Zineb Hamilou, Luigina Mollica, Juan Li, Agnes Viale, Adriana Heguy, Maryam Hassimi, Nicholas Socci, Parva K Bhatt, Mithat Gonen, Christopher E Mason, Ari Melnick, Lucy A Godley, Cameron W Brennan, Omar Abdel-Wahab, Ross L Levine
Affiliations
- PMID: 23001125
- PMCID: PMC3483435
- DOI: 10.1038/ng.2413
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis
Lambert Busque et al. Nat Genet. 2012 Nov.
Abstract
Aging is characterized by clonal expansion of myeloid-biased hematopoietic stem cells and by increased risk of myeloid malignancies. Exome sequencing of three elderly females with clonal hematopoiesis, demonstrated by X-inactivation analysis, identified somatic TET2 mutations. Recurrence testing identified TET2 mutations in 10 out of 182 individuals with X-inactivation skewing. TET2 mutations were specific to individuals with clonal hematopoiesis without hematological malignancies and were associated with alterations in DNA methylation.
Figures
Figure 1. Somatic TET2 mutations are present in normal elderly individuals with myeloid skewing and associated with epigenetic alterations
Exome sequencing identifies somatic TET2 mutation in myeloid cells of an elderly normal subject with non-random X-inactivation (A). LC/MS analysis reveals a decrease in 5-hmC with age and increased 5-mC in PMNs of elderly individuals with TET2 mutations (asterisk indicates p<0.05; arrowheads indicate comparator) (B). This is associated with site-specific hypermethylation and transcriptional silencing (C) in normal individuals with TET2 mutations as revealed by MassArray Epityper and qRT-PCR analysis in the PMNs of 6 TET2 wildtype and 6 mutant individuals. Error bars represent standard deviation relative to mean in panels B and C.
Similar articles
- TET proteins and 5-methylcytosine oxidation in hematological cancers.
Ko M, An J, Pastor WA, Koralov SB, Rajewsky K, Rao A. Ko M, et al. Immunol Rev. 2015 Jan;263(1):6-21. doi: 10.1111/imr.12239. Immunol Rev. 2015. PMID: 25510268 Free PMC article. Review. - The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.
Solary E, Bernard OA, Tefferi A, Fuks F, Vainchenker W. Solary E, et al. Leukemia. 2014 Mar;28(3):485-96. doi: 10.1038/leu.2013.337. Epub 2013 Nov 13. Leukemia. 2014. PMID: 24220273 Review. - TET2 mutation as prototypic clonal hematopoiesis lesion.
Guarnera L, Jha BK. Guarnera L, et al. Semin Hematol. 2024 Feb;61(1):51-60. doi: 10.1053/j.seminhematol.2024.01.013. Epub 2024 Feb 2. Semin Hematol. 2024. PMID: 38431463 Review. - Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.
Jakobsen NA, Turkalj S, Zeng AGX, Stoilova B, Metzner M, Rahmig S, Nagree MS, Shah S, Moore R, Usukhbayar B, Angulo Salazar M, Gafencu GA, Kennedy A, Newman S, Kendrick BJL, Taylor AH, Afinowi-Luitz R, Gundle R, Watkins B, Wheway K, Beazley D, Murison A, Aguilar-Navarro AG, Flores-Figueroa E, Dakin SG, Carr AJ, Nerlov C, Dick JE, Xie SZ, Vyas P. Jakobsen NA, et al. Cell Stem Cell. 2024 Aug 1;31(8):1127-1144.e17. doi: 10.1016/j.stem.2024.05.010. Epub 2024 Jun 24. Cell Stem Cell. 2024. PMID: 38917807 - Chronic TNF in the aging microenvironment exacerbates Tet2 loss-of-function myeloid expansion.
Quin C, DeJong EN, McNaughton AJM, Buttigieg MM, Basrai S, Abelson S, Larché MJ, Rauh MJ, Bowdish DME. Quin C, et al. Blood Adv. 2024 Aug 13;8(15):4169-4180. doi: 10.1182/bloodadvances.2023011833. Blood Adv. 2024. PMID: 38924753 Free PMC article.
Cited by
- The evolving hematopoietic niche during development.
Sánchez-Lanzas R, Jiménez-Pompa A, Ganuza M. Sánchez-Lanzas R, et al. Front Mol Biosci. 2024 Oct 2;11:1488199. doi: 10.3389/fmolb.2024.1488199. eCollection 2024. Front Mol Biosci. 2024. PMID: 39417006 Free PMC article. Review. - Somatic mutations in autoinflammatory and autoimmune disease.
Torreggiani S, Castellan FS, Aksentijevich I, Beck DB. Torreggiani S, et al. Nat Rev Rheumatol. 2024 Oct 11. doi: 10.1038/s41584-024-01168-8. Online ahead of print. Nat Rev Rheumatol. 2024. PMID: 39394526 Review. - Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2).
Armstrong AJ, Taylor A, Haffner MC, Abida W, Bryce AH, Karsh LI, Tagawa ST, Twardowski P, Serritella AV, Lang JM. Armstrong AJ, et al. Prostate Cancer Prostatic Dis. 2024 Oct 1. doi: 10.1038/s41391-024-00901-4. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 39354185 Review. - The emergence of clonal hematopoiesis as a disease determinant.
Walsh K. Walsh K. J Clin Invest. 2024 Oct 1;134(19):e180063. doi: 10.1172/JCI180063. J Clin Invest. 2024. PMID: 39352387 Free PMC article. No abstract available. - Clonal hematopoiesis and atherosclerosis.
Oren O, Small AM, Libby P. Oren O, et al. J Clin Invest. 2024 Oct 1;134(19):e180066. doi: 10.1172/JCI180066. J Clin Invest. 2024. PMID: 39352379 Free PMC article. Review.
References
- Busque L, et al. Blood. 1996;88:59. - PubMed
- Gale RE, Fielding AK, Harrison CN, Linch DC. Br J Haematol. 1997;98:512. - PubMed
- Busque L, Gilliland DG. Leukemia. 1998;12:128. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U54 CA143798/CA/NCI NIH HHS/United States
- R01 CA129831/CA/NCI NIH HHS/United States
- HHMI/Howard Hughes Medical Institute/United States
- 1R01CA129831-03S1/CA/NCI NIH HHS/United States
- 1R01CA138234-01/CA/NCI NIH HHS/United States
- F32 DK092030/DK/NIDDK NIH HHS/United States
- 1R01CA129831/CA/NCI NIH HHS/United States
- R01 CA138234/CA/NCI NIH HHS/United States
- U54CA143798-01/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical